Recent Updates
Recently added Catalysts
CGON Positive Sentiment

FIERCE BIOTECH

Wednesday, August 2, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology has successfully secured $105 million in funding to support its Phase 3 trial for bladder cancer. This significant investment aims to advance research and treatment options for patients suffering from this condition. The funding is expected to enhance the company's capabilities in addressing unmet medical needs in oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • CG Oncology successfully raised $105M for a Phase 3 trial.
  • Funding will support bladder cancer research and treatment advancements.
  • The company has a strong focus on addressing unmet medical needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Aug 2, 2023 | in-the-news
CG Oncology brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What is the purpose of the funding raised by CG Oncology?

The funding will support CG Oncology's Phase 3 trial for bladder cancer.

How much money did CG Oncology raise?

CG Oncology raised $105 million for its clinical trial.

What type of cancer is CG Oncology focusing on?

CG Oncology is focusing on bladder cancer in its research.

What phase is CG Oncology's current trial?

CG Oncology is currently conducting a Phase 3 trial.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology bladder cancer Phase 3 trial oncology research cancer treatment
Last updated: Aug 2, 2023

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →